Frequency of diminished ovarian reserve in women with multiple sclerosis in Chile: An exploratory study

Pelayo, Carolina; Ciampi, Ethel; Soler, Bernardita; Uribe-San-Martín, Reinaldo; Reyes, Ana; García, Lorena; Del-Canto, Adolfo; Gutierrez-Carquin, Leticia; Barrerra-Hormazabal, Antonia; Jürgensen-Heinrich, Lukas; Guzman-Cárcamo, Ignacio; Carvajal, Andrés; Troncoso, Carlos; Carvajal, Rodrigo; Cárcamo, Claudia

doi:10.1016/j.msard.2023.105012

Cited by 2 publications

(1 citation statement)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anti-Mullerian hormone (AMH) was thought be decreased in women with MS versus healthy women, and in women with more active disease course [33]. However, recent larger studies and a systematic review and meta-analysis on ovarian reserve in patients with multiple sclerosis suggested no significant difference in serum AMH or follicle-stimulating hormone levels, nor the ovarian volume [36 ▪ ,37]. Antral follicle count (AFC) and estradiol blood levels were significantly lower, and luteinizing hormone (LH) levels were significantly higher in in WwMS, than in controls [36 ▪ ].…”

Section: Pre-conceptionmentioning

confidence: 99%

Pregnancy and reproductive health in women with multiple sclerosis: an update

Houtchens

2024

Current Opinion in Neurology

View full text Add to dashboard Cite

Purpose of the review Multiple sclerosis (MS) is a chronic immune-mediated, inflammatory, neuro-degenerative disease of the central nervous system, prevalent in women of reproductive age. Today, many women want to start a family after MS diagnosis. There are over 20 treatments for MS, and safely navigating family planning is important. We review updated information on family planning, preconception, and peri-partum considerations, and reproductive concerns in special populations with MS. Recent findings There are no MS-related restrictions on any available and appropriate contraceptive method in women with MS. The question of MS and pregnancy outcomes following assisted reproduction, remains somewhat unsettled. In many studies, no elevated relapse risk is confirmed regardless of the type of fertility treatment. MRI status may offer better assessment of postpartum disease stability than relapse rate alone. Ongoing effective MS treatments during fertility assistance and before pregnancy, can further reduce the relapse risk. B-cell depleting therapies are emerging as safe and effective treatments for peripartum MS patients. Summary Patients with MS should receive accurate support and counseling related to their reproductive options. The general outlook on pregnancy and MS remains positive. The ever-increasing therapeutic complexity of MS calls for ongoing education and updated guidance for neuroimmunology and obstetrics healthcare providers.

show abstract

Section: Pre-conceptionmentioning

confidence: 99%